ARYx Therapeutics, Inc.
ARYXOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$16731
P/E Ratio—
52W High$0.0005
52W Low$0.000001
ARYx Therapeutics, Inc. (ARYX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ARYX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2009-12 | 2008-12 | 2007-12 | 2006-12 | 2005-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.02B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.02B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | 98.82% | 93.70% | 55.35% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.02B | $0.04B | $0.02B | $0.02B | $0.02B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.03B | $0.05B | $0.03B | $0.03B | $0.03B |
| Operating Income | ($0.03B) | ($0.03B) | ($0.03B) | ($0.03B) | ($0.03B) |
| Operating Margin %(computed) | — | -154.21% | -692.64% | -596.92% | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Net Income | ($0.03B) | ($0.03B) | ($0.03B) | ($0.03B) | ($0.03B) |
| Net Margin %(computed) | — | -158.27% | -662.84% | -576.66% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.21 | $-1.65 | $-2.93 | $-26.84 | $-30.73 |
| Wtd Avg Shares | 0.03B | 0.02B | 0.01B | 0.00B | 0.00B |
| EBITDA | ($0.03B) | ($0.03B) | ($0.03B) | ($0.03B) | ($0.03B) |
| EBITDA Margin %(computed) | — | -148.65% | -662.87% | -577.51% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more ARYx Therapeutics, Inc. data
About ARYx Therapeutics, Inc. (ARYX) Income Statement
ARYx Therapeutics, Inc. (ARYX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2009, ARYX reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.03B) — a net profit margin of —.
Frequently asked questions
ARYX · 4 questionsARYx Therapeutics, Inc. (ARYX) reported revenue of $0.00B for 2009, down 100.0% year-over-year.
ARYX revenueARYX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09